Navigation Links
Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007

JERSEY CITY, N.J.--(BUSINESS WIRE)--May 4, 2007 - Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company's next-generation calcineurin inhibitor, LX211, is the subject of two presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 6-10 in Fort Lauderdale, Florida.

The first, an oral presentation being given on May 5 during a satellite session of the American Uveitis Society by Quan Dong Nguyen, M.D. of the Wilmer Eye Institute, Johns Hopkins University and Hospitals, discusses the design of the ongoing LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) Phase 2/3 Clinical Trial Program. The three LUMINATE trials represent the first clinical development program aimed at supporting regulatory approval of a corticosteroid-sparing immunosuppressive agent in different types of sight-threatening, non-infectious uveitis.

The second, a poster presentation by Matthew A. Cunningham, senior medical student, senior author Robert Nussenblatt, MD, and collaborators from the National Eye Institute, Lux Biosciences, and Isotechnika, Inc., discusses preclinical data demonstrating the ability of subcutaneous injections of LX211 to prevent and reverse experimental autoimmune uveoretinitis (EAU) in rats. Cunningham commented, "We observed that in this animal model, LX211 could both prevent the onset of disease as well as reverse EAU at doses as low as 10 mg/kg. These preclinical results clearly support our view that LX211 may play an important future role in the treatment of uveitis."

The poster describes the induction of EAU in rats, which were then divided into three groups, designated preventative, therapeutic, and vehicle-control. Animals in the first two groups received daily subcutaneous injections of either cyclosporine A (CsA) at 40 mg/kg
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... Tengion, Inc. (Nasdaq: TNGN ), a leader in ... as its President and Chief Executive Officer. Most recently, Mr. ... and Chief Executive Officer of CCS Medical, Inc., a company ... services for patients with chronic diseases, from 2008 until completion ...
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... scheduled to present at the Oppenheimer Healthcare Conference in ... 1:00 p.m. EST/10:00 a.m. PST.  A ... from the Investor Relations page of the Company,s website ...
Cached Medicine Technology:Tengion Appoints John L. Miclot President and Chief Executive Officer 2Tengion Appoints John L. Miclot President and Chief Executive Officer 3Tengion Appoints John L. Miclot President and Chief Executive Officer 4
(Date:8/30/2014)... (PRWEB) August 30, 2014 Jake W., 18, ... while in the Back2Basics Outdoor Adventures transition program ... finish high school so I can actually start on a ... and math, and I'm done.” , He has six months ... Back2Basics program. Most clients choose to continue on to the ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 “In 2013, a ... The Jones Firm says in a recently released article on ... person was injured in an auto accident every 12 minutes, ... minutes,” they continue. “Based on the 2013 statistics, between now ... vehicle collision.” , The threat of an auto accident is ...
(Date:8/30/2014)... Miami, FL (PRWEB) August 30, 2014 Zensah®, ... new Camo Compression Leg Sleeve . The camo sleeves ... Compression Leg Sleeve collection. The camo line includes classic ... purple and magenta. , Known as tibial stress syndrome, ... side of the lower leg. Swollen and irritated muscles, stress ...
(Date:8/30/2014)... Barton Associates, an industry leading physician, ... , announces a new office location in Keene, NH, ... headquartered in Peabody, MA, with additional staffing centers in ... Jupiter, FL. , Barton Associates made the decision to ... crisis affecting the United States, a crisis that will ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 What challenges ... What are the latest trends, concerns, and considerations? ... Dr. Ken Pendleton recently spoke with Woody Wommack, Southeast ... of current issues in football recruiting. Notably, Wommack ... younger athletes, changes that he thinks are coming as ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... by Nancy Speck, PhD, professor of Cell and Developmental ... University of Pennsylvania, has discovered a molecular marker for ... in the developing embryo, which provides much-needed insights for ... in the bone marrow of adult mammals, generate all ...
... populations with a low prevalence of tuberculosis (TB), the ... in the U.S for the diagnosis of TB ... "We compared commercially available tests for latent tuberculosis ... LTBI prevalence," said James Mancuso, MD, DrPH, of the ...
... HealthDay Reporter , THURSDAY, Dec. 8 (HealthDay News) -- ... the known cosmetic and psychological advantages, a new study ... women with DCIS (ductal carcinoma in situ, an early ... Hershman, an associate professor of medicine and epidemiology at ...
... 8 (HealthDay News) -- New guidelines on treating so-called "latent" ... simplify the course of the therapy from about 9 months ... Control and Prevention. The new guidelines for public health ... expert opinion and the results of three clinical trials -- ...
... one of the coauthors of a new paper by a group ... for strong steps to be taken to control the global crisis ... of steps that need to be taken on a global scale ... a meeting the group held at the Banbury Conference Centre in ...
... Ga. A study that may help personalize pain ... at Georgia Health Sciences University. Dr. Cheedy Jaja, ... Nursing, has received a three-year National Institutes of Health ... play a role in metabolizing opioids could help physicians ...
Cached Medicine News:Health News:Penn study unlocks origins of blood stem cells 2Health News:Discordance among commercially-available diagnostics for latent TB infection 2Health News:Few Women Get Breast Reconstruction After Mastectomy: Study 2Health News:Few Women Get Breast Reconstruction After Mastectomy: Study 3Health News:CDC Issues New TB Treatment Guidelines 2Health News:New paper calls for strong steps to tackle antibiotic resistance 2Health News:Study probes genetic link to sickle cell pain management 2Health News:Study probes genetic link to sickle cell pain management 3Health News:Study probes genetic link to sickle cell pain management 4
... Radiation Protection Goggles fit ... be used by the ... leaded glass, 1.0 mm ... provide increased scatter radiation ...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Qualcraft™ Radiation Readers, Wraparound Glasses. Protect yourself and have close-vision clarity....
Medicine Products: